TrialNature medicine2024

An Omicron-specific, self-amplifying mRNA booster vaccine for COVID-19: a phase 2/3 randomized trial.

Amit Saraf et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.